CSI is a Singapore-based clinical contract research organisation (CRO) and provides cost-efficient clinical solutions. Credit: Chokniti-Studio/Shutterstock.com.

CRO ClinChoice has acquired CSI Medical Research, marking a significant expansion of its international operations.

The strategic move bolsters ClinChoice’s full-service capabilities and footprint across more than 30 countries in Asia, Europe and North America.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

CSI, established in 2017, is a Singapore-based clinical CRO providing new and cost-efficient clinical solutions.

It has a team of professionals and a network of partners across South East Asia (SEA), Australia and New Zealand (ANZ).

ClinChoice global chairman and CEO Ling Zhen stated: “This is an exciting time for ClinChoice, and we are thrilled to welcome the talented CSI team to the ClinChoice family.

“With their wide range of highly valuable service offerings and seasoned professional team, the acquisition of CSI will further expand our presence in SEA and ANZ and enhance our capability to well fulfil our clients’ needs locally and globally.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition comes at a time when the clinical research environment and infrastructure in South East Asia have seen considerable improvements.

CSI’s expertise in regional practices, ethics, regulatory needs and site operations has positioned it as a prominent player in the domestic CRO landscape.

CSI medical research founder and CEO Nelson Wong stated: “We are excited to leverage our familiarity with the SEA and ANZ regulations as well as the clinical sites within a region we call home, to assist more customers to navigate through the challenges with great speed and better cost efficiencies.

“CSI’s vision and mission in the approach to manage clinical trials are very much aligned with ClinChoice, and the company’s high-quality, efficiency and teamwork culture will be fantastic for our talented employees and clients alike.”